Innovation

Case studies explored more and less successful practices when delivering healthcare across four priority areas (screening, disease management and standardised patient pathways, rational use of medicines and healthcare associated infections). Results were used to simulate cost-savings and patient outcomes that could potentially be realised with improvements in efficiency across the European Union of 27 countries and the United Kingdom.

This year’s OHE lecture addressed the question: how should the world pay for a COVID-19 vaccine? The paper by Adrian Towse and Isobel Firth accompanying the lecture is now published. It builds on work undertaken with Kalipso Chalkidou, Rachel Silverman and Ganesh Ramakrishnan from the Center for...

OHE authors develop a supply and demand model of pharmaceutical markets to analyse the social welfare distribution between consumers (payers) and developers (industry) to set an optimal cost-effectiveness threshold (CET).

The COVID-19 pandemic has highlighted the necessity of finding health solutions in an unprecedentedly short length of time. However, the first treatments, tests and vaccines will only offer partial solutions. Competing follow-on technologies will offer better or complementary health benefits. It is essential that health systems do not put all of their eggs in one basket.

A move towards paying multiple prices for medicines (depending on what they are used for) could address a commonly cited problem in drug development and increase patient access. Our latest consulting report investigates whether key stakeholders are onboard.

In place of OHE’s 2020 Annual Lecture, Adrian Towse will give a webinar-lecture on June 25th on payment models for a COVID-19 vaccine.

He will be discussing options for funding the development and manufacture of a vaccine, reflecting on their strengths and weaknesses, considering what may happen with no regional or global collaboration. Analysis will consider the work of Gavi and others to construct a global vaccine market that delivers for all citizens.

The need for social distancing in light of COVID-19 has led to an unprecedented increase in reliance on digital technologies by both health care providers and patients. While the trend towards digitalisation of health care allows for potential improvements in access, its impact on health outcomes and health inequalities must be carefully considered to ensure they contribute to social welfare and not detract from it.

Research by OHE and the University of Washington into how uncertainty-related novel elements of value could be included in an Augmented Cost-Effectiveness Analysis has been published in Journal of Managed Care & Specialty Pharmacy (JMCP). The research discusses what has been or could be done to measure these elements and looks at empirical research to date.

A COVID-19 vaccine is needed now, but timelines (12-18 months) create large market risk. By the time a vaccine is ready, the crisis may have passed. A CGD Note explores three options: business as usual – which may lead to promotion of an inferior vaccine or fierce country competition for supply – and two models (cost- or value-based), with countries pre-committing to purchases meeting specified efficacy. The authors prefer a value-based model.

Adrian Towse presented evidence that transparency of process reduced corruption and improved competition. Evidence was, however, against price transparency for on-patent medicines. It will reduce access in low income countries. In generic markets, price transparency could improve efficiency, although it risks collusion by suppliers. There is therefore a case for buyers sharing, but not publishing, price data for off-patent medicines.

Pages

Subscribe to RSS - Innovation